Accelerate Diagnostics Inc

Accelerate Diagnostics — 38th Annual J.P. Morgan Healthcare Conference 2020

23 slides from Accelerate Diagnostics's conference presentation, Jan 15, 2020

  1. Slide 1: 38th Annual J.P. Morgan Healthcare Conference

    Slide 1: 38th Annual J.P. Morgan Healthcare Conference

    38TH ANNUAL J.P. Morgan Healthcare Conference Jack Phillips Incoming CEO January 2020

  2. Slide 2: Cautionary Note On Forward-Looking Statements

    Slide 2: Cautionary Note On Forward-Looking Statements

    Cautionary Note On Forward-Looking Statements © Copyright 2020 Accelerate Diagnostics, Inc. All Rights Reserved. The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are registered trademarks of Accelerate Diagnostics, Inc. All other trade

  3. Slide 3: Our Purpose and Mission

    Slide 3: Our Purpose and Mission

    OUR PURPOSE We deliver lifesaving answers for patients with serious infections 3 OUR MISSION Expand our market leadership in Rapid ID/AST by delivering innovation with clear clinical and financial value for health systems and patients

  4. Slide 4: Sepsis: 270,000 deaths in U.S. annually

    Slide 4: Sepsis: 270,000 deaths in U.S. annually

    270,000 deaths in U.S. annually1 AIDS Breast Cancer Prostate Cancer Lung Cancer SEPSIS 1 in 3 patient deaths in U.S. hospitals 1. Centers for Disease Control and Prevention (cdc.gov/sepsis/datareports) 2. Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP): http

  5. Slide 5: Optimizing antibiotics within the first hours is critical

    Slide 5: Optimizing antibiotics within the first hours is critical

    Optimizing antibiotics within the first 24 hours is critical 80% of sepsis deaths could be prevented with rapid diagnosis and treatment 7.6% decrease in chance of survival per hour of delay of effective therapy Kumar A, et al. Duration of hypotension before initiation of effective antimicrobial ther

  6. Slide 6: Today's standard of care

    Slide 6: Today's standard of care

    Today’s standard of care Can take up to 69 hours ‘TIME TO RESULT ‘TIME TO OPTIMAL THERAPY TTR TTOT CONVENTIONAL METHODS. 40 48 56 64 n HouRS ACCELERATE

  7. Slide 7: The New Standard of Care: Accelerate Pheno system

    Slide 7: The New Standard of Care: Accelerate Pheno system

    The New Standard of Care Accelerate Pheno® system 7 1. Texas Health Huguley Hospital. Self-reported data (October 2019). 2. University of Iowa Health Care. Data presented at IDWeek™ (October 2019).

  8. Slide 8: Patient & Economic Impact of rapid action based on Accelerate Pheno results

    Slide 8: Patient & Economic Impact of rapid action based on Accelerate Pheno results

    Patient & Economic Impact of rapid action based on Accelerate Pheno® results T–12 hrs Blood drawn, patient started on empiric therapy (cefepime) 8 hrs TTR: Accelerate Pheno® system results: multi-drug-resistant E. coli 12 hrs TTOT: Patient therapy changed to meropenem 9 CHILDREN’S HOSPITAL LOS ANGEL

  9. Slide 9: The ID/AST Testing Market

    Slide 9: The ID/AST Testing Market

    The ID/AST Testing Market First mover advantage on substantial IVD market 10 ID/AST restated market value1 $3.7B ID/AST tests per annum2 All Other Micro Samples2 Blood Resp. 135M tests North America EMEA China Total Blood: 2.3 1.9 2.5 6.7 Respiratory: 0.9 0.9 0.7 2.5 All Other Micro Samples:2 34.7 2

  10. Slide 10: The ID/AST Testing Market

    Slide 10: The ID/AST Testing Market

    The ID/AST Testing Market First mover advantage on substantial IVD market 10 ID/AST restated market value1 $3.7B ID/AST tests per annum2 All Other Micro Samples2 Blood Resp. 135M tests North America EMEA China Total Blood: 2.3 1.9 2.5 6.7 Respiratory: 0.9 0.9 0.7 2.5 All Other Micro Samples:2 34.7 2

  11. Slide 11: How we're doing in the market: Preliminary 2019 key results

    Slide 11: How we're doing in the market: Preliminary 2019 key results

    How we’re doing in the market Preliminary 2019 key results 0 140 280 420 560 700 2017 2018 2019 $0 $2 $4 $6 $8 $10 2017 2018 2019 Gross Margin: ~50% Net Cash Burn: $58M Cash Balance: $109M Global Contracted Phenos Consolidated Revenue Other Key Results2 304 placements in 2019 $9.3M in 2019 11 78 280

  12. Slide 12: 2020 Expectations

    Slide 12: 2020 Expectations

    2020 Expectations Momentum continuing to build Revenue Net cash burn 2020 $16–18M $49M YOY% ~100% ~(15%)

  13. Slide 13: 2020 Priorities

    Slide 13: 2020 Priorities

    U.S. Commercial Excellence Focused Geographic Expansion Targeted Investments in Innovation 1 2 3 13 2020 Priorities

  14. Slide 14: U.S. Commercial Excellence

    Slide 14: U.S. Commercial Excellence

    1 U.S. Commercial Excellence 14 2020 Priorities

  15. Slide 15: Powered by Evidence

    Slide 15: Powered by Evidence

    Powered by Evidence 15 Cost Savings $3,100 /patient1 Length of Stay –6.1 days1 –4.7 days2 –2.4 days3 –5.9 days1,* –2.2 days4,* 1. Werner Forssmann Hospital. Data presented at DIVI Congress (December 2019). 2. Arnot Ogden Medical Center. Self-reported data (October 2019). 3. University of Arkansas fo

  16. Slide 16: Customer KOLs span key geographies/segments

    Slide 16: Customer KOLs span key geographies/segments

    Customer KOLs span key geographies/segments • Current customer base enables regional referral strategy • Customers across all segments • Leverage KOL base as advocates

  17. Slide 17: Reengineering go-live process

    Slide 17: Reengineering go-live process

    Reengineering go-live process Improving time from contract to reliable annuity § Overhauled process in 4Q19 § Operational focus to improve multi-site delays § Long-term goal is 50% reduction to go-live $45k $102k Live Pheno Instruments + Not Yet Live US Annuity Current Average Per Instrument Annuity

  18. Slide 18: Focused Geographic Expansion

    Slide 18: Focused Geographic Expansion

    2 Focused Geographic Expansion 18 2020 Priorities

  19. Slide 19: Update on Non-US Markets

    Slide 19: Update on Non-US Markets

    Update on Non-US Markets EMEA China § An important long-term market § Focus on improving annuity § Leveraging mounting clinical evidence to expand utility from current ICU niche to all blood testing § Initiated NMPA registration/trial process § Building KOL network affiliated with China National Act

  20. Slide 20: Targeted Investments in Innovation

    Slide 20: Targeted Investments in Innovation

    Targeted Investments 3 in Innovation 20 2020 Priorities

  21. Slide 21: Targeted Investments in Innovation

    Slide 21: Targeted Investments in Innovation

    Targeted Investments in Innovation Accelerate Pheno® System Assay Expansion § Current blood test improvements: new drugs and AST features § Respiratory: analytical studies ongoing Next Generation Platform § Low-cost / high-throughput § Unlocks other clinical micro samples § Established multiplex cap

  22. Slide 22: Growth Strategy

    Slide 22: Growth Strategy

    Growth Strategy Platform innovation & geographic plan significantly expands available market1 $1.0B Current Addressable Market $3.7B 22 Adding Lower Respiratory Assay Expansion into China Blood Market Expanding Lab Footprint with Low Acuity Samples $1.3B $2.0B § Mature gross margins of ~70% § Strate

  23. Slide 23: Summary

    Slide 23: Summary

    Summary WHO WE ARE A diagnostics company based in Arizona, founded in 2012, with a mission of reducing the impact of sepsis and antibiotic resistance through rapid diagnosis of serious infections. THE PROBLEM Due to the overuse of antibiotics, the human and hospital costs of treating conditions like

Source: SEC EDGAR · 8-K filed Jan 15, 2020

More decks from Accelerate Diagnostics Inc